Resverlogix Corp RVXCF

Primary Symbol: T.RVX

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > Brown envelopes

<< Previous

Bullboard Posts

Next >>

Post by gericon Jan 16, 2022 5:06pm

272 Views

Post# 34322250

Brown envelopes

Since the ethics approval on Oct 12 what has been accomplished?......Nothing. All we get from DM is the proverbial brown envelope with everything he states. No one ever did get to know what was in that brown envelope, much as I don't think we will ever get anything else. I'm tired of his game. Why he hasn't been booted out long ago speaks to the impotence of the BoD.

<< Previous

Bullboard Posts

Next >>

Africa Oil collects more shares under buyback program